Mathematical modeling of drug-induced receptor internalization in the HER2-positive SKBR3 breast cancer cell-line

About 20% of breast cancer tumors over-express the HER2 receptor. Trastuzumab, an approved drug to treat this type of breast cancer, is a monoclonal antibody directly binding at the HER2 receptor and ultimately inhibiting cancer cell growth. The goal of our study was to understand the early impact o...

Descripción completa

Detalles Bibliográficos
Autores principales: Fehling-Kaschek, Mirjam, Peckys, Diana B., Kaschek, Daniel, Timmer, Jens, Jonge, Niels de
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722142/
https://www.ncbi.nlm.nih.gov/pubmed/31481718
http://dx.doi.org/10.1038/s41598-019-49019-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722142/
https://www.ncbi.nlm.nih.gov/pubmed/31481718
http://dx.doi.org/10.1038/s41598-019-49019-x

Ejemplares similares